OCUL · Ocular Therapeutix Inc.
AI read · Good for OCUL
The AI's read
EyePoint's pivotal trial missed its primary endpoint while showing some secondary gains. OCUL is trading up as the market re-rates the competitive field in wet AMD. Partly priced in. OCUL is +7% today but RSI 25.8 and well under its 52-week high, so buyers haven't fully run the story yet. OCUL's SOL-1 success and a planned NDA in the fourth quarter of 2026 give the move some teeth. Bottom line, we lean bullish on the news because the rival miss removes a near-term competitive threat and validates the TKI class. Stay cautious given overall market consolidation and whipsaw risk; this is company-specific alpha, not a market trend.